Slide 1: LOTIS-5 Topline Results Presentation
LOTIS - 5 Topline Results Presentation JUNE 3, 2026
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a re
Slide 3: Agenda
LOTIS - 5 Topline Results 3 Agenda Introduction Ameet Mallik Chief Executive Officer 01 Clinical Highlights Mohamed Zaki Chief Medical Officer 02 03 Q&A 04 Next Steps Ameet Mallik Chief Executive Officer
Slide 4: ZYNLONTA is an approved, highly-potent, single-agent anti-CD19 ADC in r/r DLBCL
LOTIS - 5 Topline Results 4 ZYNLONTA ® is an approved, highly - potent, single - agent anti - CD19 ADC in r/r DLBCL ZYNLONTA ( loncastuximab tesirine ) is a CD19 - directed ADC indicated as monotherapy for the treatment of adult patients with relapsed or refractory large B - cell lymphoma after two
Slide 5: Advancing ZYNLONTA Development Into 2L+ B-Cell Lymphomas
LOTIS - 5 Topline Results 5 Advancing ZYNLONTA Development Into 2L+ B - Cell Lymphomas DLBCL = diffuse large b - cell lymphoma; FL = follicular lymphoma; MZL = marginal zone lymphoma, IIT = Investigator initiated tria l → 2L+ treatment choice is based largely on achieving a rapid and durable complet
Slide 6: ZYNLONTA Potential Role in Two Distinct r/r DLBCL Segments
LOTIS - 5 Topline Results 6 ZYNLONTA has the Potential to Play a Role in Two Distinct r/r DLBCL Segments Through a Complementary Approach + Based on internal market research conducted July to August 2024 (n=160 US Hem/ Oncs ), glofitamab ODAC briefing book dated May 20, 2025, and Komodo claims data
Slide 7: LOTIS-5: Phase 3 Confirmatory Trial of ZYNLONTA with Rituximab in 2L+ DLBCL
LOTIS - 5 Topline Results 7 LOTIS - 5: Phase 3 Confirmatory Trial of ZYNLONTA in Combination with Rituximab in 2L+ DLBCL Lonca 150 µg/kg + rituximab 375 mg/m2 Q3W for 2 cycles, then Lonca 75 µg/kg + rituximab 375 mg/m2 Q3W for up to 6 additional cycles Part 1 safety run - in (N=20) previously publis
Slide 8: Patient population enrolled generally balanced between arms
LOTIS - 5 Topline Results 8 Patient population enrolled generally balanced between arms Baseline Patient Characteristics Percentages may not add due to rounding. Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin; ECOG = Eastern Cooperative On
Slide 9: Summary of key results LOTIS-5: Efficacy
LOTIS - 5 Topline Results 9 Summary of key results LOTIS - 5: Efficacy PFS = progression free survival; HR = hazard ratio; OS = overall survival; NALT = new anti - lymphoma therapy; CR = complete respo nse; Data cut off: February 16, 2026. Study met primary PFS endpoint with statistical significance
Slide 10: Met primary endpoint of PFS with statistical significance
LOTIS - 5 Topline Results 10 Met primary endpoint of PFS with statistical significance Progression Free Survival by IRC *Other reasons include starting NALT without confirmed PD, no postbaseline assessment, or consent withdrawal. IRC = Independent Review Committee, PFS = progression free survival; L
Slide 11: Progression Free Survival by Investigator Assessment
LOTIS - 5 Topline Results 11 Difference from IRC assessment reflects lower censoring in investigator reported data Progression Free Survival by Investigator Assessment *Other reasons include starting NALT without confirmed PD, no postbaseline assessment, or consent withdrawal. IRC = Independent Revi
Slide 12: Time to Treatment Failure
ťť ċ ť „ Ř ĺ î Ū è ť ϱ [ Ėı Ė ťϙ ‹ Ū Ř ŽĖ Ž Í īϙ ( Ŝ ť Ėı Í ť ô Ŝ ® Ė ť ēϙ b Ū ı æ ô Řϙ ĺ ċϙ ‹ Ūæ Ĥ ô è ť Ŝϙ Í ťϙ ‡ ĖŜ ħ ͏ ϟ ͏ ͏ ϟ ͑ ͏ ϟ ͓ ͏ ϟ ͕ ͏ ϟ ͗ ͐ ϟ ͏ ‹ Ū Ř ŽĖ Ž Í īϙ „ Ř ĺ æ Í æ Ė ī Ė ťƅ ť ϙ Ř Ė Ŝ ħ ϙϡ [ ib ϱ ‡ ‡ ϱ @( a i³ ͑ ͐ ͏ ͖ ͗ ͒ ͗ ͐ ͘ ͘ ͒ ͏ ͑ ͐ ͏ ͓ ͒ ͑ ͐ ͕ ͐ ͐ ͏ ͏ ͑ ͔ ͏ ͔ ͏ ͏ ͖ ͔
Slide 13: Key secondary efficacy endpoint of OS showed no detrimental effect
OS sensitivity analysis using IPCW method with adjustment for impact of NALT showed meaningful difference between treatment arms (HR=0.82, 95% CI: 0.72 - 0.93) LOTIS - 5 Topline Results 13 Key secondary efficacy endpoint of OS showed no detrimental effect Overall Survival Rate of NALT in test vs. co
Slide 14: Overall Response Rate by IRC
14 Lonca-R (N=210) R-GemOx (N=210) ORR: 58.1% (n=122) ORR: 45.2% (n=95) PR: 18.6% (n=39) CR: 39.5% (n=83) PR: 18.6% (n=39) CR: 26.7% (n=56) LOTIS - 5 Topline Results 14 Improvement in ORR and CR demonstrated with ZYNLONTA plus rituximab vs. R - GemOx Overall Response Rate by IRC Percentages may not
Slide 15: Duration of Response/Complete Response by IRC
LOTIS - 5 Topline Results 15 At 24 months, 48.5% of patients achieving CR remained in CR with ZYNLONTA plus rituximab vs.16.7% with R - GemOx Duration of Response/Complete Response by IRC Lonca - R = loncastuximab tesirine - lpyl with rituximab; NE = not estimable; R - GemOx = rituximab + gemcitabin
Slide 16: Summary of key results LOTIS-5: Safety
LOTIS - 5 Topline Results 16 Summary of key results LOTIS - 5: Safety SAE = serious adverse event; TEAE = treatment emergent adverse event Data cut off: February 16, 2026. Overall TEAE rates similar between arms Similar rates of overall Grade ≥3 TEAEs >5% were observed across both arms – Hematologic
Slide 17: Overall Summary of Treatment Emergent Adverse Events
LOTIS - 5 Topline Results 17 Overall Summary of Treatment Emergent Adverse Events TEAE reporting window defined as 105 days after last dose of study treatment or start of NALT, whichever is earlier. Median TEA E follow - up time: 3.9 months on LONCA - R and 2.5 months on R - GEMOX TEAE = treatment e
Slide 18: Grade 3 or Higher Treatment Emergent Adverse Events >5%
R - GemOx (N=197), n (%) Lonca - R (N=204), n (%) Grouped Term / Preferred Term 150 (76.1%) 151 (74.0%) Patients with any grade 3 or higher TEAE 117 (59.4 % ) 83 (40.7 % ) Blood and lymphatic system disorders (SOC) 67 (34.0%) 52 (25.5%) Neutropenia 65 (33.0%) 25 (12.3%) Thrombocytopenia 32 (16.2%) 2
Slide 19: Time from First Dose to Key Safety Events
LOTIS - 5 Topline Results 19 Rates of TEAEs impacted by longer overall TEAE observation time in test vs control arm Time from First Dose to Key Safety Events* *Key safety events defined as any Grade ≥3 TEAE; serious TEAE, or TEAE leading to study drug withdrawal; If TEAE occurred, ce nso r at the la
Slide 20: Cause of Grade 5 Treatment Emergent Adverse Events
LOTIS - 5 Topline Results 20 Cause of Grade 5 Treatment Emergent Adverse Events a: One patient with bacterial inguinal infection and one patient gastrointestinal infection; b: two patients with general det eri oration due to disease progression; c: one patient died in sleep in setting of progressive
Slide 21: Upcoming Potential Milestones
LOTIS - 5 Topline Results 21 Upcoming Potential Milestones → Pre - sBLA meeting (Aug) → sBLA filing (Q4 2026) → Data presentation (Q4 26) → Compendia inclusion (1H27) → Confirmatory approval (2H 27) ZYNLONTA LOTIS - 5 → Data presentation (Q4 26) → Compendia inclusion (1H 27) → Assess regulatory stra
Slide 22: Our sincere thanks
Our sincere thanks … to the patients, caregivers, investigators and clinical trial sites for their participation in LOTIS - 5 and to the ADC Therapeutics team who contributed to this important trial.
Slide 23: Appendix
Appendix
Slide 24: Drug Exposure
LOTIS - 5 Topline Results 24 Drug Exposure (Safety Population N=401) *Dose intensity is defined by total dose divided by treatment duration. Relative dose intensity is defined as actual dose int ens ity divided by planned dose intensity, reflecting the extent of dose reduction and dose delay during
Slide 25: Forest Plot of Progression Free Survival by IRC
LOTIS - 5 Topline Results 25 Forest Plot of Progression Free Survival by IRC Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin. ITT population, N=420; IRC = independent review committee Data cut off: February 16, 2026. 25 In favor of Lonca -
Slide 26: Prespecified Analysis: Progression Free Survival by IRC by Age
LOTIS - 5 Topline Results 26 Prespecified Analysis: Progression Free Survival by IRC by Age Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin. Treated population, N=401; Data cut off: February 16, 2026 ≥ 75 years old ͏ ͏ ͐ ͐ ͑ ͑ ͒ ͒ ͓ ͓ ͔ ͔ ͕
Slide 27: Prespecified Analysis: Overall Survival by Age
LOTIS - 5 Topline Results 27 Prespecified Analysis: Overall Survival by Age Lonca - R = loncastuximab tesirine - lpyl with rituximab; R - GemOx = rituximab + gemcitabine + oxaliplatin. Treated population, N=401; Data cut off: February 16, 2026. ‡ ϱ @( a i³ ͏ ϟ ͏ ͏ ϟ ͐ ͏ ϟ ͑ ͏ ϟ ͒ ͏ ϟ ͓ ͏ ϟ ͔ ͏ ϟ ͕ ͏
Slide 28: TEAEs Leading to Any Study Drug Withdrawal
Treatment Emergent Adverse Events Leading to Any Study Drug Withdrawal LOTIS - 5 Topline Results 28 >2% in Either Treatment Arm by Group Term or Preferred Term *Group Term is based on either System Organ Class (SOC) or AEs of Special Interest (AESI) category TEAE reporting window defined as 105 days
Slide 29: Serious Treatment Emergent Adverse Events
LOTIS - 5 Topline Results 29 >2% in Either Treatment Arm by Group Term or Preferred Term Serious Treatment Emergent Adverse Events *Group Term is based on either System Organ Class (SOC) or AEs of Special Interest (AESI) category Serious Adverse Event (SAE): An AE resulting in death, life - threaten